Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion - Pharmaceutical Technology

Thoracic oncologists previously touted the potential of Bayer's Hyrnuo in HER2-mutant NSCLC in both the first- and second-line settings. Thoracic oncologists previously touted Hyrnuo’s potential in HER2-mutant NSCLC in both the first- and second-line settings. Hyrnuo is now indicated for frontline use in a specific type of HER2-mutant NSCLC. Credit: UA Creative Microstocks / Shutterstock.com. Bayer has landed an accelerated US approval for its non-small cell lung cancer (NSCLC) therapy, Hyrnuo (sevabertinib), expanding the drug’s role into the frontline treatment setting within an indication linked to poor patient prognosis. As per the US Food and Drug Administration’s (FDA) recommendation, Hyrnuo…

Source: Pharmaceutical Technology